PACB 📈 Pacific Biosciences of - Overview

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US69404D1081

PACB: Sequencing Systems, Consumable Products, Reagent Kits, Binding Kits

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California. Web URL: https://www.pacb.com

Additional Sources for PACB Stock

PACB Stock Overview

Market Cap in USD 603m
Sector Healthcare
Industry Medical Devices
GiC Sub-Industry Life Sciences Tools & Services
IPO / Inception 2010-10-27

PACB Stock Ratings

Growth 5y -59.9%
Fundamental -49.5%
Dividend -
Rel. Strength Industry -1651
Analysts 3.87/5
Fair Price Momentum 1.67 USD
Fair Price DCF -

PACB Dividends

No Dividends Paid

PACB Growth Ratios

Growth Correlation 3m 41.1%
Growth Correlation 12m -55.5%
Growth Correlation 5y -36.1%
CAGR 5y -17.76%
CAGR/Mean DD 5y -0.28
Sharpe Ratio 12m -0.79
Alpha -134.23
Beta 2.29
Volatility 103.31%
Current Volume 10838.3k
Average Volume 20d 9308.4k
What is the price of PACB stocks?
As of December 21, 2024, the stock is trading at USD 1.97 with a total of 10,838,282 shares traded.
Over the past week, the price has changed by +0.51%, over one month by +14.53%, over three months by +7.95% and over the past year by -79.82%.
Is Pacific Biosciences of a good stock to buy?
Probably not. Based on ValueRay Fundamental Analyses, Pacific Biosciences of (NASDAQ:PACB) is currently (December 2024) not a good stock to buy. It has a ValueRay Fundamental Rating of -49.52 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of PACB as of December 2024 is 1.67. This means that PACB is currently overvalued and has a potential downside of -15.23%.
Is PACB a buy, sell or hold?
Pacific Biosciences of has received a consensus analysts rating of 3.87. Therefor, it is recommend to buy PACB.
  • Strong Buy: 6
  • Buy: 1
  • Hold: 8
  • Sell: 0
  • Strong Sell: 0
What are the forecast for PACB stock price target?
According to ValueRays Forecast Model, PACB Pacific Biosciences of will be worth about 1.8 in December 2025. The stock is currently trading at 1.97. This means that the stock has a potential downside of -8.12%.
Issuer Forecast Upside
Wallstreet Target Price 3 53.3%
Analysts Target Price 13.8 599%
ValueRay Target Price 1.8 -8.1%